A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial.

Chronic total coronary occlusions constitute a sub-group of lesions at very high risk of restenosis after successful percutaneous coronary intervention. The sirolimus-eluting coronary stent is the only drugeluting stent that has demonstrated to reduce angiographic restenosis and the need for new revascularisation procedures in comparison with bare-metal stents in randomised clinical trials focusing on these lesions. Everolimus-eluting stents have shown to offer optimal angiographic and clinical outcomes in comparison with bare-metal stents and paclitaxel-eluting stents, but no randomised trials have tested the device in chronic total occlusions. The CIBELES (non-acute Coronary occlusIon treated By EveroLimusEluting Stent) will randomise 208 patients with chronic total coronary occlusions in 13 centres from Portugal and Spain to receive everolimus- or sirolimus-eluting coronary stents. The primary endpoint will be angiographic in-stent late loss.

[1]  J. López-Sendón,et al.  Periprocedural (30-day) risk of myocardial infarction after drug-eluting coronary stent implantation: a meta-analysis comparing cobalt-chromium and stainless steel drug-eluting coronary stents. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[3]  P. Serruys,et al.  Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: a lighthouse and as a toe in the water. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  Deepak L. Bhatt,et al.  Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis , 2008, The Lancet.

[5]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[6]  G. Biondi-Zoccai,et al.  Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). , 2008, Minerva cardioangiologica.

[7]  P. Serruys,et al.  One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  Bernard Chevalier,et al.  European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  J. López-Sendón,et al.  Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. , 2007, European heart journal.

[10]  B. Rensing,et al.  Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.

[11]  P. Fitzgerald,et al.  Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). , 2006, The American journal of cardiology.

[12]  Seung‐Jung Park,et al.  Comparison between sirolimus- and Paclitaxel-eluting stents for the treatment of chronic total occlusions. , 2006, The Journal of invasive cardiology.

[13]  P. Serruys,et al.  One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  H. Figulla,et al.  Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. , 2004, Journal of the American College of Cardiology.

[15]  C. Vassanelli,et al.  Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. , 1998, Journal of the American College of Cardiology.